Controlled release copolymer formulation with improved release kinetics
The present invention provides a constant release copolymer composition adapted for use in a controlled release formulation for a bioactive agent, such as a formulation adapted for implantation within a patient's body tissues as a depot to release the agent over a period of time, wherein the copolymer provides a substantially constant rate of release of the bioactive agent over the time period for which the depot persists in the body tissues. The copolymer includes a PLG copolymer and a PLG oligomer of about 5-10 kDa average molecular weight, which can lack free carboxylic acid groups. When the PLG copolymer is a low burst copolymer, the constant release copolymer composition is a low burst, constant release copolymer composition adapted for implantation in the body tissues of a mammal, wherein a substantially constant rate of release of the bioactive agent is achieved.
1. A controlled release formulation comprising a constant release copolymer composition, a bioactive agent, and an organic solvent having at least a slight solubility in body fluid wherein the constant release copolymer composition comprises a mixture of a PLG copolymer and a PLG oligomer, the PLG copolymer is a poly(lactide-glycolide) copolymer without a core diol unit, the poly(lactide-glycolide) copolymer having a monomer molar proportion of up to 100 mole % lactide to 100 mole % glycolide, the PLG oligomer is a poly(lactide-glycolide) oligomer with a core diol unit, the PLG oligomer having a monomer molar proportion of up to 100 mole % lactide, the PLG oligomer having a weight average molecular weight of about 5 to 10 kDa, and the PLG oligomer being present in about 2 wt % to about 10 wt % of the total weight of the PLG copolymer and PLG oligomer.
2. The controlled release formulation of claim 1 wherein the organic solvent is N-methylpyrrolidone, dimethylacetamide, dimethylformamide, dimethylsulfoxide, or a polyethyleneglycol.
3. The controlled release formulation of claim 1 wherein the bioactive agent comprises a peptide, a protein, a steroid, a prostaglandin, a hormone or hormone regulating substance, an anti-psychotic, an anti-inflammatory, an analgesic or a nucleic acid.
4. The controlled release formulation of claim 1 comprising as a bioactive agent risperidone, octreotide, leuprolide, or GHRP-1.
5. The controlled release formulation of claim 1 wherein the weight average molecular weight of the PLG oligomer is about 7 to about 8 kDa.
6. The controlled release formulation of claim 1 wherein the PLG oligomer comprises more than about 60% lactide residues on a molar basis.
7. A method of preparing the controlled release formulation of claim 1 for a bioactive agent comprising combining a PLG oligomer having a weight average molecular weight of about 5 to about 10 kDa, and a PLG copolymer, to provide a constant release copolymer composition, then forming the controlled release formulation by combining the constant release copolymer composition with an organic solvent having at least a slight solubility in body fluids and with the bioactive agent.
8. The method of claim 7 wherein the PLG copolymer is a low burst copolymer.
9. The method of claim 7 wherein the PLG copolymer is a PLG(p), a core diol PLG, or a SFE-purified PLG.
10. The method of claim 7 wherein the PLG copolymer is a PLGH copolymer.
11. The method of claim 7 wherein the organic solvent is water-soluble.
12. The method of claim 7 wherein the organic solvent is N-methylpyrrolidone, dimethylacetamide, dimethylformamide, dimethylsulfoxide, or a polyethyleneglycol.
13. The method of claim 7 wherein the bioactive agent comprises a peptide, a protein, a steroid, a prostaglandin, a hormone or hormone regulating substance, an anti-psychotic, an anti-inflammatory, an analgesic or a nucleic acid.
14. The method of claim 7 wherein the bioactive agent is risperidone, octreotide, leuprolide, or GHRP-1.
15. The method of claim 7 wherein the constant release copolymer composition comprises about 4-6 wt % of the PLG oligomer.
16. The method of claim 7 wherein the PLG oligomer comprises at least about 50 mole % lactide residues and has a weight average molecular weight of about 5-10 kDa.
17. The method of claim 7 wherein the PLG oligomer has at least about a 65 mole % of lactide residues.
18. The method of claim 7 wherein the oligomer comprises 100 mole % of lactide residues.
19. The method of claim 7 wherein the PLG oligomer has a weight average molecular weight of about 7-8 kDa.
20. A method of administering a bioactive agent to a patient in need thereof, over a prolonged period of time, wherein a substantially constant rate of release of the bioactive agent is achieved, comprising administering to the patient in need thereof, the controlled release formulation of claim 1 .
21. The method of claim 20 wherein the formulation is administered as a depot.
22. The method of claim 21 wherein the depot is emplaced subcutaneously.
23. The method of claim 20 wherein the patient suffers from a malcondition, the bioactive agent being adapted to treat, arrest, or palliate the malcondition.
24. The method of claim 23 wherein the malcondition is prostate cancer and the agent comprises leuprolide.
25. The method of claim 23 wherein the malcondition is acromegaly and the agent comprises octreotide.
26. The method of claim 23 wherein the malcondition is psychosis and the agent comprises risperidone.
27. The method of claim 23 wherein the malcondition is pain and the agent is an analgesic or an anti-inflammatory.
28. A kit adapted for administration to a patient of the controlled release formulation of claim 1 comprising a first container comprising the bio active agent, and a second container comprising the constant release copolymer composition, optionally dissolved in the organic solvent, or, optionally, a third container comprising the organic solvent, wherein the kit is adapted such that respective contents of the first, the second, and optionally the third container can be mixed for administration to the patient, optionally further comprising instructional material.
29. The kit of claim 28 wherein the first container, the second container, or both, comprise a syringe.
30. The kit of claim 29 wherein the first container comprises a first syringe and the second container comprises a second syringe, and the kit further comprises a coupling such that the contents of the first syringe and the second syringe can be mixed by reciprocally interchanging the contents of the first syringe and the second syringe.
31. The kit of claim 28 wherein the bioactive agent is present in the first container in form of a dry, dehydrated, or lyophilized solid prior to mixing with the contents of the second and, optionally, the third container.
32. The kit of claim 28 wherein the respective contents of the containers have previously been sterilized.
33. The kit of claim 32 wherein the respective contents of the containers have previously been sterilized by gamma radiation or by electron beam radiation.